168 related articles for article (PubMed ID: 29693647)
21. Response to sequential treatment with lymphoblastoid interferon-alpha in patients with Ph+ chronic myeloid leukemia unresponsive to recombinant interferon-alpha (rIFN alpha 2a) and neutralizing-rIFN alpha 2a antibodies negative.
Russo D; Candoni A; Grattoni R; Minisini R; Rosti G
Haematologica; 1997; 82(3):348-50. PubMed ID: 9234589
[TBL] [Abstract][Full Text] [Related]
22. [Autoimmune phenomena during interferon-alpha therapy for hematopoietic disorders].
Iguchi T; Nishimaki J; Kawakubo K; Shimamoto T; Iwase O; Suzuki A; Kuriyama Y; Ito Y; Tauchi T; Yaguchi M; Miyazawa K; Kimura Y; Ohyashiki K
Gan To Kagaku Ryoho; 2003 Nov; 30(12):1911-6. PubMed ID: 14650958
[TBL] [Abstract][Full Text] [Related]
23. Interferon-alpha antibodies in patients with renal cell carcinoma treated with recombinant interferon-alpha-2A in an adjuvant multicenter trial. The Delta-P Study Group.
Prümmer O
Cancer; 1993 Mar; 71(5):1828-34. PubMed ID: 8448744
[TBL] [Abstract][Full Text] [Related]
24. Inhibition of endogenous interferon beta by neutralizing antibodies against recombinant interferon beta.
Sominanda A; Lundkvist M; Fogdell-Hahn A; Hemmer B; Hartung HP; Hillert J; Menge T; Kieseier BC
Arch Neurol; 2010 Sep; 67(9):1095-101. PubMed ID: 20837854
[TBL] [Abstract][Full Text] [Related]
25. Hybrid transgenic immune tolerant mouse model for assessing the breaking of B cell tolerance by human interferon beta.
van Beers MM; Sauerborn M; Gilli F; Hermeling S; Brinks V; Schellekens H; Jiskoot W
J Immunol Methods; 2010 Jan; 352(1-2):32-7. PubMed ID: 19857496
[TBL] [Abstract][Full Text] [Related]
26. Anti-interferon alpha antibodies and autoantibodies in patients with Behçet's disease uveitis treated with recombinant human interferon alpha-2a.
Aydinoglu-Candan Ö; Araz-Erşan B; Gul A; Badur S; Tugal-Tutkun I
Graefes Arch Clin Exp Ophthalmol; 2015 Mar; 253(3):457-65. PubMed ID: 25500983
[TBL] [Abstract][Full Text] [Related]
27. Imatinib and pegylated IFN-α2b discontinuation in first-line chronic myeloid leukemia patients following a major molecular response.
Koskenvesa P; Kreutzman A; Rohon P; Pihlman M; Vakkila E; Räsänen A; Vapaatalo M; Remes K; Lundán T; Hjorth-Hansen H; Vakkila J; Simonsson B; Mustjoki S; Porkka K
Eur J Haematol; 2014; 92(5):413-20. PubMed ID: 24372965
[TBL] [Abstract][Full Text] [Related]
28. Quantification of BCR-ABL transcripts in CML patients in cytogenetic remission after interferon-alpha-based therapy.
Martinelli G; Testoni N; Amabile M; Bonifazi F; De Vivo A; Farabegoli P; Terragna C; Montefusco V; Ottaviani E; Saglio G; Russo D; Baccarani M; Rosti G; Tura S
Bone Marrow Transplant; 2000 Apr; 25(7):729-36. PubMed ID: 10745258
[TBL] [Abstract][Full Text] [Related]
29. Interferon-alpha in the treatment of myeloproliferative diseases.
Kissová J
Vnitr Lek; 2019; 65(11):699-703. PubMed ID: 31906676
[TBL] [Abstract][Full Text] [Related]
30. Appearance and disappearance of neutralizing antibodies during interferon-beta therapy.
Sorensen PS; Koch-Henriksen N; Ross C; Clemmesen KM; Bendtzen K;
Neurology; 2005 Jul; 65(1):33-9. PubMed ID: 15888603
[TBL] [Abstract][Full Text] [Related]
31. Anti-interferon antibodies to interferon-alpha 2b: results of comparative assays and clinical perspective.
Spiegel RJ; Jacobs SL; Treuhaft MW
J Interferon Res; 1989 Sep; 9 Suppl 1():S17-24. PubMed ID: 2553829
[TBL] [Abstract][Full Text] [Related]
32. Pegylated interferon alpha - 2a is clinically effective and tolerable in myeloproliferative neoplasm patients treated off clinical trial.
Gowin K; Jain T; Kosiorek H; Tibes R; Camoriano J; Palmer J; Mesa R
Leuk Res; 2017 Mar; 54():73-77. PubMed ID: 28113109
[TBL] [Abstract][Full Text] [Related]
33. Humoral response to recombinant interferon-alpha 2b in patients receiving recombinant interferon-alpha 2b therapy.
von Wussow P; Jakschies D; Freund M; Deicher H
J Interferon Res; 1989 Sep; 9 Suppl 1():S25-31. PubMed ID: 2809276
[TBL] [Abstract][Full Text] [Related]
34. Early reduction of BCR-ABL mRNA transcript levels predicts cytogenetic response in chronic phase CML patients treated with imatinib after failure of interferon alpha.
Merx K; Müller MC; Kreil S; Lahaye T; Paschka P; Schoch C; Weisser A; Kuhn C; Berger U; Gschaidmeier H; Hehlmann R; Hochhaus A
Leukemia; 2002 Sep; 16(9):1579-83. PubMed ID: 12200666
[TBL] [Abstract][Full Text] [Related]
35. Chronic clonal myeloproliferative disease associated with a t(5;21) translocation. Complete but transient hematologic and cytogenetic remission induced by interferon-alpha.
Marmont AM; Sessarego M
Leukemia; 1995 Jun; 9(6):977-80. PubMed ID: 7596188
[TBL] [Abstract][Full Text] [Related]
36. Development and characterization of a non-cell-based assay to assess the presence of neutralizing antibodies to interferon-beta in clinical samples.
Cludts I; Meager A; Thorpe R; Wadhwa M
J Immunol Methods; 2013 Sep; 395(1-2):37-44. PubMed ID: 23831137
[TBL] [Abstract][Full Text] [Related]
37. Neutralizing antibodies to interferon.
Noronha A
Neurology; 2007 Jun; 68(24 Suppl 4):S16-22. PubMed ID: 17562846
[TBL] [Abstract][Full Text] [Related]
38. Development of neutralizing interferon antibodies after treatment with recombinant interferon-alpha 2b in patients with malignant carcinoid tumors.
Oberg K; Alm GV
J Interferon Res; 1989 Sep; 9 Suppl 1():S45-9. PubMed ID: 2809277
[TBL] [Abstract][Full Text] [Related]
39. An association between autoreactive antibodies and anti-interferon-beta antibodies in multiple sclerosis.
Garg N; Weinstock-Guttman B; Bhasi K; Locke J; Ramanathan M
Mult Scler; 2007 Aug; 13(7):895-9. PubMed ID: 17468449
[TBL] [Abstract][Full Text] [Related]
40. Quantification of neutralizing antibodies to human type I interferons using division-arrested frozen cells carrying an interferon-regulated reporter-gene.
Lallemand C; Meritet JF; Erickson R; Grossberg SE; Roullet E; Lyon-Caen O; Lebon P; Tovey MG
J Interferon Cytokine Res; 2008 Jun; 28(6):393-404. PubMed ID: 18593334
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
